Rani Therapeutics (US:RANI) 智通财经网·2025-10-17 15:48Core Viewpoint - Rani Therapeutics experienced a significant stock surge of over 265%, reaching a new annual high of $1.76, following the announcement of a collaboration agreement with Chugai Pharmaceutical worth up to $1.085 billion [1] Company Summary - Rani Therapeutics has entered into a collaboration agreement with Chugai Pharmaceutical, which includes an upfront payment of $10 million and potential milestone payments totaling up to $750 million for technology transfer and development, $100 million for sales milestones, and single-digit royalties [1] - The collaboration focuses on Rani Therapeutics' oral delivery technology for biologics, specifically utilizing its RaniPill® platform for the development of oral antibodies and treatments for rare diseases [1] - The partnership will apply to Chugai Pharmaceutical's rare disease antibody projects, validating the application value of Rani Therapeutics' technology [1]